Anti-CD69 Antibody, clone 1J4 ZooMAb^® Rabbit Monoclonal

Quality Control Testing

Evaluated by Western Blotting in KG-1 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected CD69 in KG-1 cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected CD69 in lysates from HUT-78 cells, human thymus tissue, mouse spleen tissue, and rat thymus tissue.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected CD69 in human tonsil tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound with CD69 peptide with at least one thousand-fold (1,000X) higher affinity than with non-specific control peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 1J4 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects CD69. It targets an epitope within 18 amino acids from the C-terminal extracellular domain.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Early activation antigen CD69 (UniProt: Q07108; also known as Activation inducer molecule (AIM), BL-AC/P26, C-type lectin domain family 2 member C, EA1, Early T-cell activation antigen p60, GP32/28, Leukocyte surface antigen Leu-23, MLR-3) is encoded by the CD69 (also known as CLEC2C) gene (Gene ID: 969) in human. CD69 is a type II transmembrane glycoprotein belonging to the C-type lectin superfamily. It exists as a disulfide-linked homodimer composed of two subunits, each containing an extracellular C-type lectin-like domain (CTLD), a single transmembrane domain, and a short cytoplasmic tail. CD69 is post-translationally modified through glycosylation, producing subunits of 28-32 kDa. It is expressed predominantly by activated immune cells, including T cells, B cells, NK cells, neutrophils, monocytes, and platelets, serving as an early activation marker due to its rapid upregulation upon cell activation. CD69 plays a critical role in regulating immune responses, including lymphocyte retention and migration within lymphoid organs. By interacting with ligands such as Galectin-1 and other molecules, CD69 modulates cytokine production, including IFN- , IL-17, and IL-22, and influences the differentiation of T-cell subsets, such as regulatory T cells (Tregs) and tissue-resident memory T cells (TRMs). It also counteracts sphingosine-1-phosphate receptor 1 (S1P1) signaling, contributing to lymphocyte retention in tissues. CD69 is involved in metabolic reprogramming of immune cells, particularly through the mTOR pathway, which further integrates its function in immune activation and homeostasis. CD69 is widely expressed in hematopoietic cells under physiological and pathological conditions, including autoimmune diseases such as type 1 diabetes and multiple sclerosis. Its dysregulated expression in diseases is linked to altered immune cell trafficking, cytokine profiles, and tissue inflammation. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

KLH-conjugated linear peptide corresponding to 18 amino acids from the C-terminal extracellular domain of human CD69.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany